Migraine: Keeping the Beast at Bay

News
Slideshow

Do you know what drugs current guidelines recommend? Get an 8-slide update, here.

About 38% of migraineurs need preventive therapy, but only about 3% to 13% currently use it, according to the American Academy of Neurology (AAN). Since the AAN published guidelines for migraine prevention in 2000, new clinical studies have addressed and readdressed the efficacy and safety of migraine preventive therapies.The short slide show above reviews guideline-endorsed pharmacotherapy for migraine prevention, behavioral interventions, and new research on difficult comorbid conditions. 

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific therapies belong in primary care setting, Jessica Ailani, MD
Related Content
Structured Lifestyle Program Yields Statistically Significant Cognitive Gains in US POINTER Trial

Structured Lifestyle Program Yields Statistically Significant Cognitive Gains in US POINTER Trial

Sydney Jennings
August 5th 2025
Article

AAIC 2025. Structured lifestyle interventions significantly enhanced cognitive function in older adults at risk for dementia, highlighting the importance of healthy behaviors.

Make It Routine: Screening for Cognitive Decline in Primary Care

Make It Routine: Screening for Cognitive Decline in Primary Care

Anna Chodos, MD, MPH;Sydney Jennings
August 5th 2025
Podcast

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025 / Image credit: ©Artur/AdobeStock

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025

Sydney Jennings
August 5th 2025
Article

Four-year data show lecanemab slows clinical decline in early Alzheimer disease and maintains a consistent safety profile.

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Sydney Jennings
August 5th 2025
Podcast

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Donanemab Showed Sustained Cognitive Benefit Over 3 Years in Early Alzheimer Disease / Image credit: ©LIGHTFIELD STUDIOS/AdobeStock

Donanemab Showed Sustained Cognitive Benefit Over 3 Years in Early Alzheimer Disease

Sydney Jennings
August 5th 2025
Article

Three-year follow-up data from the TRAILBLAZER-ALZ 2 extension trial supported early initiation and limited-duration dosing.

Alzheimer's Association Releases First Clinical Guideline on Use of Blood-Based Biomarker Tests / image credit ©ryandi/stock.adobe.com

Alzheimer's Association Releases First Clinical Guideline on Use of Blood-Based Biomarker Tests

Grace Halsey
August 5th 2025
Article

The guideline is the first in a series that will focus on diagnosis, treatment, and care of Alzheimer disease and all other dementias, according to the association.

© 2025 MJH Life Sciences

All rights reserved.